Ceramide belongs to a class of bio-active organic compounds
referred to as sphingolipids.
This class of compounds has been
shown to play important roles in many cellular processes including cell growth
and proliferation, growth arrest and most importantly, apoptosis – programmed cell
death. Furthermore, research studies
have strongly implicated sphingolipid signaling dysfunction in tumor
progression – metastasis. In addition,
sphingolipids seem to play a role in the effect of chemotherapy and radiation
upon cancer progression in patients with metastatic disease.
The current data strongly suggests that the enzyme acid ceramidase
(AC) is implicated in both tumor growth and resistance to various therapeutic
modalities as suggested above. AC is an
enzyme that catalyzes the breakdown of ceramide to sphingosine and fatty acid
(see diagram below).
AC over expression
has been found in association with certain metastatic cancers including prostate
cancer. A decrease in the intracellular levels
of ceramide has been shown to result in a decrease in apoptosis that would
ordinarily lead to cell death for proliferating tumor cells.
As a consequence of these data, Daniele Piomelli, the Louise
Turner Arnold Chair in Neurosciences at UCI, and colleagues at the Italian
Institute of Technology, have also established an association with over
expression of AC and metastatic disease in melanoma patients. This group has proceeded to successfully develop
drugs that effectively inhibit AC in an attempt to restore an appropriate level
of apoptosis and slow down tumor progression.
No comments:
Post a Comment